Market Herald logo


Be the first with the news that moves the market
  • Actinogen has received successful trial results for its cognitive improvement drug Xanamem
  • It is expected Xanamem may play a role in treating Alzheimer’s disease, bipolar disorder and schizophrenia
  • Actinogen’s share price peaked at 378 per cent this morning with shares at 4.3 cents apiece

Medical company Actinogen is up a whopping 378 per cent following midday trade after revealing successful trial results of its cognitive improvement drug.

Over 12 weeks, the elderly subjects who took daily doses of 20 milligrams of Xanamem – Actinogen’s cognitive improvement drug – recorded “significant improvement” compared to those taking a placebo.

According to the company, “this is the first time Xanamem has shown such a clear, statistically significant cognitive improvement in humans.”

A previous trial of Xanamem didn’t deliver the results the company were hoping for, the lead investigator Professor Michael Woodward detailed.

“It is just so pleasing and encouraging to see this positive efficacy data for Xanamem, following the disappointment of the XanADu trial,” Professor Michael said.

Continuing he added: “There have been so many past failures with the development of Alzheimer’s drugs, so these promising results offer renewed hope for a treatment breakthrough for this devastating disease.”

The XanADu trial, which tested 10-milligram doses of Xanamem, was safe, but didn’t improve cognition.

The most recent trial, Xanamem in Healthy Elderly Subjects (XanaHES), showed patients taking 20-milligram doses of the drug had reduced serum cortisol levels.

“These results from the XanaHES study provide Actinogen with the evidence of Xanamem’s ability to enhance cognition and inhibit cortisol production,” Actinogen Medicial Clinical Advisory Board member Professor Jeff Cummings said.

Results demonstrated in the XanaHES trail put the company in a good position to work towards creating a treatment for Alzheimer’s disease, bipolar disorder and schizophrenia.

CEO of Actinogen Dr Bill Ketelbey said the results are “hugely important for the development of Xanamem and for the potential for Xanamem to treat Alzheimer’s disease and other conditions associated with cognitive impairment.”

Shares in Actinogen are trading at 4.3 cents apiece after a 378 per cent boost today, as of 1:26 pm AEST.

ACW by the numbers
More From The Market Herald
The Market Herald Video

" PainChek (ASX:PCK) to receive govt funding for children’s disability app

PainChek (ASX:PCK) has been awarded a $392,820 grant from the Western Australia State Government's Future Health…
The Market Herald Video

" Prescient Therapeutics (ASX:PTX) granted key US patent for OmniCar platform

Prescient Therapeutics (ASX:PTX) has been granted a key US patent for its OmniCAR universal immune receptor…

" Antisense Therapeutics (ASX:ANP) dosing of muscular dystrophy drug on hold

Antisense Therapeutics (ASX:ANP) applies for partial clinical hold that limits dosing of its drug for muscular…
Antisense Therapeutics (ASX:ANP) - MD and CEO, Mark Diamond

" Antisense Therapeutics (ASX:ANP) to present new data

Antisense Therapeutics (ASX:ANP) announces its new proteomics data will be presented in a virtual congress.